May 05, 2026

Prescribing Outside the Exam Room

A DEA case exposes how controlled substances can move outside clinical oversight.

Conexiant

April 30, 2026

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

Conexiant

April 30, 2026

Urgent Care, Unchecked Power

An unsupervised clinic model and blurred boundaries expose how oversight can fail in outpatient care.

Conexiant

April 29, 2026

FDA Updates Lumateperone Label With Relapse-Prevention Data

Label update incorporates randomized withdrawal trial findings showing delayed time to relapse and consistent safety profile in schizophrenia

Conexiant

April 29, 2026

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

April 21, 2026

Two-Drug HIV Regimen Gains FDA Approval

Phase 3 trials showed noninferior viral suppression vs standard three-drug therapy with similar safety outcomes

Conexiant

April 20, 2026

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Conexiant

April 16, 2026

FDA Signals New Testosterone Pathway

Agency invites sponsors to pursue low libido indication

Conexiant

April 02, 2026

USDA Alerts on Lead in Walmart Chicken Nuggets

Detected lead could be up to five times FDA’s interim reference level for children

Conexiant

April 01, 2026

Inside Access, Outside the Rules

Two federal cases highlight alleged misuse of professional roles in health care settings

Conexiant